

Connecting via Winsock to STN

Welcome to STN International! Enter x:x



LOGINID:ssseptal203pxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	6	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	11	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	14	JUL 28	STN Viewer performance improved
NEWS	15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	16	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	18	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	21	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	23	SEP 29	IFICLS enhanced with new super search field
NEWS	24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	27	OCT 07	Multiple databases enhanced for more flexible patent number searching



```

chain nodes :
10 17 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
1-11 5-18 8-10 12-17 21-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-7 3-9 5-18 7-8 8-9 18-19 18-23 19-20 20-21 21-22 22-23
exact bonds :
1-11 8-10 12-17 21-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:33:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 307 TO ITERATE

100.0% PROCESSED 307 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L2 4 SEA SSS FUL L1

=> file medline caplus wpids

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'MEDLINE' ENTERED AT 14:34:09 ON 07 OCT 2008

FILE 'CAPLUS' ENTERED AT 14:34:09 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

=> s l2

SAMPLE SEARCH INITIATED 14:34:13 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 40
PROJECTED ANSWERS: 1 TO 40

L3 35 L2

=> s l3 and (nausea or vomit? or emesis)

L4 6 L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> d l4 1-6 ibib, abs, hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2008:771031 CAPLUS

DOCUMENT NUMBER: 149:104693

TITLE: Compounds with a combination of cannabinoid-CB1
antagonism and acetylcholinesterase inhibition and
their preparation

INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.; Shadid,
Belal

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 48pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008074816	A1	20080626	WO 2007-EP64169	20071219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080153867	A1	20080626	US 2007-957948	20071217
PRIORITY APPLN. INFO.:			EP 2006-126584	A 20061220
			US 2006-875808P	P 20061220
OTHER SOURCE(S):	MARPAT	149:104693		
GI				



- AB This invention concerns compds. of formula I [I = A-(T)n-B, wherein A is essential structural element of known CB1 antagonist; T is a (un)saturated linear carbon liner; B is essential structural element of known acetylcholinesterase inhibitor; N is 0 and 1] with a combination of cannabinoid-CB1 antagonism and cholinesterase inhibition, to pharmaceutical compds. containing these compds., to methods for preparing the compds., methods for preparing intermediates useful for their synthesis, and methods for preparing compns. The invention also relates to the uses of such compds. and compns., particularly for treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficits, traumatic brain injury, drug dependence, addiction and substance abuse. Compds. of formula II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their CB1 antagonistic activity and their acetylcholinesterase inhibitory activity.
- IT 99487-26-ODP, MCI-225, pharmacophoric element, conjugates with CB1 antagonist pharmacophoric element
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of compds. with both CB1 receptor antagonistic and acetylcholinesterase inhibiting activities)
- RN 99487-26-0 CAPLUS
- CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 2007:1243410 CAPLUS
DOCUMENT NUMBER: 147:491675
TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine for dosage forms
INVENTOR(S): Cooper, Martin Ian; Frampton, Christopher Stephen
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 49pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070254891	A1	20071101	US 2007-728947	20070327
WO 2008051282	A2	20080502	WO 2007-US7816	20070327
WO 2008051282	A3	20080731		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2006-788338P P 20060331
US 2006-808603P P 20060526


AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride (MCI-225) crystalline forms. The present invention is also directed to compns. including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders. Thus, maturation study of MCI-225 was carried out using a diverse set of 25 solvents chosen based on their dielec. constant, dipole moment and functionality. In general, the neat solvents gave Form II and the solvents with 5% water added gave Form I of MCI-225. However, there were one or two exceptions. In neat hexane, toluene, cumene and tetraline, measurements showed either Form I alone or a mixture with Form II. Without wishing to be bound by any particular theory, it is believed that this may be due to low or very low solubility of the compound in these solvents. In isopropanol (IPA), NMP, MeOH, DMF and DMSO with 5% water, measurements showed only Form II. These materials were generally highly crystalline and most were suitable for single crystal work. Again, without wishing to be bound by any particular theory, it is believed that, because Form I is a 1:1 hydrate, solns. with a higher activity of water will have a greater tendency to produce Form I. Also, MCI-225 caused a significant dose-dependent increase in bladder capacity following acetic acid irritation in cats, with individual dose significance attained at the 30 mg/kg dose. These data supported the initial pos. findings in the rat, demonstrating that MCI-225 was effective in increasing bladder capacity in commonly utilized models of overactive

bladder in two species. These results were also predictive of the efficacy of MCI-225 in the treatment of benign prostatic hyperplasia (BPH), for example, the irritative symptoms of BPH.

IT 99487-25-9D, salts 99487-26-0, MCI-225
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1204654 CAPLUS
DOCUMENT NUMBER: 147:462326
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives,
and therapeutic use
INVENTOR(S): Cooper, Martin Ian
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 80pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	----	-----	-----

WO 2007120445 A1 20071025 WO 2007-US7633 20070327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20070254899 A1 20071101 US 2007-728966 20070327
 PRIORITY APPLN. INFO.: US 2006-788565P P 20060331
 US 2006-808905P P 20060526


OTHER SOURCE(S): MARPAT 147:462326

AB The invention discloses salts of thieno[2,3-d]pyrimidine derivs., including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The invention also discloses compns. including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

IT 99487-26-0, MCI-225
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-26-0 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 99487-25-9D, salts
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-25-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (soluble salts of thienopyrimidine derivs., and therapeutic use)
 RN 99487-25-9 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
 (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1030476 CAPLUS
 DOCUMENT NUMBER: 145:389426
 TITLE: Method of treating disorders and conditions using
 peripherally restricted 5-HT3 antagonists and
 inhibitors
 INVENTOR(S): Thor, Karl Bruce; Ricca, Daniel J.
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 129pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006105117	A2	20061005	WO 2006-US11334	20060327
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 US 20060293309 A1 20061228 US 2006-389887 20060327
 PRIORITY APPLN. INFO.: US 2005-666253P P 20050328
 OTHER SOURCE(S): MARPAT 145:389426
 AB The invention features compds., e.g. 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compds. affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compds. are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT3 receptors can be lessened or reduced using the peripherally restricted compds. of the invention. Compds. of the invention are quaternary ammonium derivs. of MCI-225. Compound preparation is included.
 IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
 RN 99487-26-0 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
 RN 99487-25-9 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610068 CAPLUS

DOCUMENT NUMBER: 141:134099

TITLE: Method of treating nausea, vomiting
, or retching by administering a 5-HT3 receptor
antagonist and noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Thor, Karl Bruce

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA

SOURCE: PCI Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062624	A2	20040729	WO 2004-US809	20040113
WO 2004062624	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204827	A1	20040729	AU 2004-204827	20040113
AU 2004204827	B2	20060629		
CA 2512022	A1	20040729	CA 2004-2512022	20040113
US 20040147510	A1	20040729	US 2004-757981	20040113
EP 1567163	A2	20050831	EP 2004-701830	20040113
EP 1567163	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006748	A	20051220	BR 2004-6748	20040113
CN 1750827	A	20060322	CN 2004-80004249	20040113
JP 2006516977	T	20060713	JP 2006-500937	20040113
AT 359079	T	20070515	AT 2004-701830	20040113
NZ 541009	A	20070928	NZ 2004-541009	20040113
ES 2285407	T3	20071116	ES 2004-701830	20040113
US 20040254171	A1	20041216	US 2004-846978	20040514
US 20040254172	A1	20041216	US 2004-846979	20040514
US 7094786	B2	20060822		
IN 2005DN02961	A	20070413	IN 2005-DN2961	20050704
MX 2005PA07379	A	20060210	MX 2005-PA7379	20050707
ZA 2005005816	A	20060927	ZA 2005-5816	20050720
PRIORITY APPLN. INFO.:			US 2003-440076P	P 20030113
			US 2003-492478P	P 20030804
			US 2004-757981	A1 20040113
			WO 2004-US809	W 20040113

OTHER SOURCE(S): MARPAT 141:134099


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. A pharmaceutical composition comprising: (a) a first amount of a 5-HT3 receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is

also claimed.

IT 99487-25-9 99487-25-9D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method of treating nausea, vomiting, or retching
by administering a 5-HT₃ receptor antagonist and noradrenaline reuptake
inhibitor)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)




RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)




L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:203673 CAPLUS
DOCUMENT NUMBER: 140:229481
TITLE: New therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-
(1-piperazinyl)thieno[2,3-d]pyrimidine
INVENTOR(S): Cavalla, David; Gristwood, Robert William
PATENT ASSIGNEE(S): Arachnova Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019948	A1	20040311	WO 2003-GB3720	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,			

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2496695 A1 20040311 CA 2003-2496695 20030828
AU 2003259373 A1 20040319 AU 2003-259373 20030828
AU 2003259373 B2 20060309
EP 1539172 A1 20050615 EP 2003-791032 20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003013836 A 20050621 BR 2003-13836 20030828
CN 1678322 A 20051005 CN 2003-820617 20030828
JP 2006500427 T 20060105 JP 2004-569724 20030828
US 20060167005 A1 20060727 US 2005-525532 20050725
GB 2002-20064 A 20020829
GB 2003-16115 A 20030709
WO 2003-GB3720 W 20030828
PRIORITY APPLN. INFO.:
AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine or a
salt thereof has value in the treatment of fibromyalgia, obesity, weight
gain, and other conditions.
IT 99487-25-9 476148-82-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-
piperazinyl)thieno[2,3-d]pyrimidine)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



RN 476148-82-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,
hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HC1

● H2O

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:33:28 ON 07 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:33:36 ON 07 OCT 2008

L1 STRUCTURE UPLOADED

L2 4 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008

L3 35 S L2

L4 6 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> s l3 and (cancer or tumor)

L5 0 L3 AND (CANCER OR TUMOR)

=> s l3 and chemotherap?

L6 6 L3 AND CHEMOTHERAP?

=> d l6 1-6 ibib, abs, hitstr

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:771031 CAPLUS

DOCUMENT NUMBER: 149:104693

TITLE: Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition and their preparation

INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.; Shadid, Belal

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 48pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008074816	A1	20080626	WO 2007-EP64169	20071219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080153867	A1	20080626	US 2007-957948	20071217
PRIORITY APPLN. INFO.:			EP 2006-126584	A 20061220
			US 2006-875808P	P 20061220
OTHER SOURCE(S):		MARPAT 149:104693		
GI				




II

AB This invention concerns compds. of formula I [I = A-(T)n-B, wherein A is essential structural element of known CBI antagonist; T is a (un)saturated linear carbon linker; B is essential structural element of known acetylcholinesterase inhibitor; N is 0 and 1] with a combination of cannabinoid-CBI antagonism and cholinesterase inhibition, to pharmaceutical compns. containing these compds., to methods for preparing the compds., methods for preparing intermediates useful for their synthesis, and methods for preparing compns. The invention also relates to the uses of such compds. and compns., particularly for treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficits, traumatic brain injury, drug dependence, addiction and substance abuse. Compds. of formula II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their CBI antagonistic activity and their acetylcholinesterase inhibitory activity.

IT 99487-26-ODP, MCI-225, pharmacophoric element, conjugates with CBI antagonist pharmacophoric element
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of compds. with both CBI receptor antagonistic and acetylcholinesterase inhibiting activities)

RN 99487-26-0 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1030476 CAPLUS
 DOCUMENT NUMBER: 145:389426
 TITLE: Method of treating disorders and conditions using peripherally restricted 5-HT3 antagonists and inhibitors
 INVENTOR(S): Thor, Karl Bruce; Ricca, Daniel J.
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 129pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006105117	A2	20061005	WO 2006-US11334	20060327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20060293309 A1 20061228 US 2006-389887 20060327 PRIORITY APPLN. INFO.: US 2005-666253P P 20050328 OTHER SOURCE(S): MARPAT 145:389426				

AB The invention features compds., e.g. 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compds. affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compds. are particularly useful in treating disorders or conditions ameliorated by antagonism of


peripheral 5-HT3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT3 receptors can be lessened or reduced using the peripherally restricted compds. of the invention. Compds. of the invention are quaternary ammonium derivs. of MCI-225. Compound preparation is included.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:878266 CAPLUS

DOCUMENT NUMBER: 141:343543

TITLE: Method of treating lower urinary tract disorders with 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination

INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Fraser, Matthew O.

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 104 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089288	A2	20041021	WO 2004-US10088	20040402
WO 2004089288	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004227945	A1	20041021	AU 2004-227945	20040402
AU 2004227945	B2	20061026		
CA 2519379	A1	20041021	CA 2004-2519379	20040402
US 20040209869	A1	20041021	US 2004-817332	20040402
US 6846823	B2	20050125		
EP 1539181	A2	20050615	EP 2004-758741	20040402
EP 1539181	B1	20070627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR JP 2006522144 T 20060928 JP 2006-509595 20040402 EP 1795196 A2 20070613 EP 2007-5612 20040402 EP 1795196 A3 20080206				
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR AT 365554 T 20070715 AT 2004-758741 20040402 ES 2290741 T3 20080216 ES 2004-758741 20040402 US 20050020577 A1 20050127 US 2004-863771 20040607 US 20050026909 A1 20050203 US 2004-863770 20040607 US 7115606 B2 20061003 US 20050272719 A1 20051208 US 2005-122940 20050504 US 20050282799 A1 20051222 US 2005-124580 20050506 AU 2007200317 A1 20070215 AU 2007-200317 20070125				
PRIORITY APPLN. INFO.:			US 2003-461022P	P 20030404
			US 2003-496502P	P 20030820
			US 2004-536341P	P 20040113
			AU 2004-227945	A3 20040402
			EP 2004-758741	A3 20040402
			US 2004-817332	A1 20040402
			WO 2004-US10088	W 20040402
			US 2004-863771	A1 20040607

OTHER SOURCE(S): MARPAT 141:343543


AB The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary

frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount Administration of MCI-225 to rat or cat models of overactive bladder caused a significant dose-dependent increase in bladder capacity.


IT 99487-25-9 99487-25-9D, salts
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination for treating lower urinary tract disorders)
 RN 99487-25-9 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-26-0, MCI-225
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as 5-HT3 antagonist and noradrenaline reuptake inhibitor; 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination for treating lower urinary tract disorders)
 RN 99487-26-0 CAPLUS
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610068 CAPLUS

DOCUMENT NUMBER: 141:134099

TITLE: Method of treating nausea, vomiting, or retching by administering a 5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Thor, Karl Bruce

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA

SOURCE: PCI Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062624	A2	20040729	WO 2004-US809	20040113
WO 2004062624	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204827	A1	20040729	AU 2004-204827	20040113
AU 2004204827	B2	20060629		
CA 2512022	A1	20040729	CA 2004-2512022	20040113
US 20040147510	A1	20040729	US 2004-757981	20040113
EP 1567163	A2	20050831	EP 2004-701830	20040113
EP 1567163	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006748	A	20051220	BR 2004-6748	20040113
CN 1750827	A	20060322	CN 2004-80004249	20040113
JP 2006516977	T	20060713	JP 2006-500937	20040113
AT 359079	T	20070515	AT 2004-701830	20040113
NZ 541009	A	20070928	NZ 2004-541009	20040113
ES 2285407	T3	20071116	ES 2004-701830	20040113
US 20040254171	A1	20041216	US 2004-846978	20040514
US 20040254172	A1	20041216	US 2004-846979	20040514
US 7094786	B2	20060822		
IN 2005DN02961	A	20070413	IN 2005-DN2961	20050704
MX 2005PA07379	A	20060210	MX 2005-PA7379	20050707
ZA 2005005816	A	20060927	ZA 2005-5816	20050720
PRIORITY APPLN. INFO.:			US 2003-440076P	P 20030113

US 2003-492478P P 20030804
US 2004-757981 A1 20040113
WO 2004-US809 W 20040113


OTHER SOURCE(S): MARPAT 141:134099

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT₃ antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. A pharmaceutical composition comprising: (a) a first amount of a 5-HT₃ receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.

IT 99487-25-9 99487-25-9D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating nausea, vomiting, or retching by administering a 5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor)


RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610067 CAPLUS

DOCUMENT NUMBER: 141:134098

TITLE: Method of treating functional bowel disorders by administering a 5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062623	A2	20040729	WO 2004-US807	20040113
WO 2004062623	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ			
AU 2004204825	A1	20040729	AU 2004-204825	20040113
AU 2004204825	B2	20070719		
CA 2512983	A1	20040729	CA 2004-2512983	20040113
US 20040147509	A1	20040729	US 2004-757364	20040113
EP 1558081	A2	20050803	EP 2004-701811	20040113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004006749	A	20051220	BR 2004-6749	20040113
JP 2006516976	T	20060713	JP 2006-500936	20040113
NZ 541008	A	20070928	NZ 2004-541008	20040113
US 20040254168	A1	20041216	US 2004-838789	20040503
US 20040254169	A1	20041216	US 2004-841317	20040507
US 20040254170	A1	20041216	US 2004-841318	20040507
US 20040259862	A1	20041223	US 2004-841319	20040507
US 20050032780	A1	20050210	US 2004-866593	20040611
US 20050192270	A1	20050901	US 2005-119357	20050429
IN 2005DN02967	A	20070413	IN 2005-DN2967	20050704
MX 2005PA07381	A	20060210	MX 2005-PA7381	20050707
ZA 2005005817	A	20060426	ZA 2005-5817	20050720
US 20060217391	A1	20060928	US 2006-441905	20060526
PRIORITY APPLN. INFO.:			US 2003-440077P	P 20030113
			US 2003-492480P	P 20030804
			US 2004-757364	A1 20040113
			WO 2004-US807	W 20040113
			US 2005-119357	A1 20050429

OTHER SOURCE(S): MARPAT 141:134098

AB The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT₃ antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea. A pharmaceutical composition comprising: (a) a first amount

of a 5-HT₃ receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.

IT 99487-25-9 99487-25-9D, salts


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(method of treating functional bowel disorders by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)


RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:203673 CAPLUS

DOCUMENT NUMBER: 140:229481

TITLE: New therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-

(1-piperazinyl)thieno[2,3-d]pyrimidine

INVENTOR(S): Cavalla, David; Gristwood, Robert William

PATENT ASSIGNEE(S): Arachnova Therapeutics Ltd., UK

SOURCE: PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019948	A1	20040311	WO 2003-GB3720	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA	2496695	A1 20040311 CA 2003-2496695 20030828
AU	2003259373	A1 20040319 AU 2003-259373 20030828
AU	2003259373	B2 20060309
EP	1539172	A1 20050615 EP 2003-791032 20030828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
BR	2003013836	A 20050621 BR 2003-13836 20030828
CN	1678322	A 20051005 CN 2003-820617 20030828
JP	2006500427	T 20060105 JP 2004-569724 20030828
US	20060167005	A1 20060727 US 2005-525532 20050725


PRIORITY APPLN. INFO.:
 GB 2002-20064 A 20020829
 GB 2003-16115 A 20030709
 WO 2003-GB3720 W 20030828

AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain, and other conditions.

IT 99487-25-9 476148-82-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)


RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 476148-82-0 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H₂O

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:33:28 ON 07 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:33:36 ON 07 OCT 2008
STRUCTURE UPLOADED

L1 4 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008

L3 35 S L2
L4 6 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)
L5 0 S L3 AND (CANCER OR TUMOR)
L6 6 S L3 AND CHEMOTHERAP?

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	84.33	262.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.60	-9.60

STN INTERNATIONAL LOGOFF AT 14:35:50 ON 07 OCT 2008

